GT Biopharma, Inc. – NASDAQ:GTBP
GT Biopharma stock price today
GT Biopharma stock price monthly change
GT Biopharma stock price quarterly change
GT Biopharma stock price yearly change
GT Biopharma key metrics
Market Cap | 8.04M |
Enterprise value | 11.07M |
P/E | -0.84 |
EV/Sales | N/A |
EV/EBITDA | -0.37 |
Price/Sales | N/A |
Price/Book | 1.41 |
PEG ratio | -0.01 |
EPS | -7.05 |
Revenue | N/A |
EBITDA | -12.78M |
Income | -9.63M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGT Biopharma stock price history
GT Biopharma stock forecast
GT Biopharma financial statements
| Jun 2023 | 0 | -1.99M | |
|---|---|---|---|
| Sep 2023 | 0 | -2.41M | |
| Dec 2023 | 0 | -2.96M | |
| Mar 2024 | 0 | -2.26M |
| 2027 | 67.7M | -31.13M | -45.99% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-05-15 | -0.14 | -0.17 |
|---|
| Jun 2023 | 18144000 | 6.38M | 35.17% |
|---|---|---|---|
| Sep 2023 | 16148000 | 6.14M | 38.04% |
| Dec 2023 | 14109000 | 6.63M | 47.01% |
| Mar 2024 | 9912000 | 4.6M | 46.41% |
| Jun 2023 | -1.93M | 2.65M | 0 |
|---|---|---|---|
| Sep 2023 | -1.96M | 1.84M | 0 |
| Dec 2023 | -2.04M | 478K | -400K |
| Mar 2024 | -4.16M | 5.03M | 0 |
GT Biopharma alternative data
| Aug 2023 | 2 |
|---|---|
| Sep 2023 | 2 |
| Oct 2023 | 2 |
| Nov 2023 | 2 |
| Dec 2023 | 2 |
| Jan 2024 | 2 |
| Feb 2024 | 2 |
| Mar 2024 | 2 |
| Apr 2024 | 2 |
| May 2024 | 2 |
| Jun 2024 | 2 |
| Jul 2024 | 2 |
GT Biopharma other data
| Period | Buy | Sel |
|---|---|---|
| Apr 2023 | 100000 | 0 |
| Quarter | Transcript |
|---|---|
| Q2 2021 13 Aug 2021 | Q2 2021 Earnings Call Transcript |
-
What's the price of GT Biopharma stock today?
One share of GT Biopharma stock can currently be purchased for approximately $1.32.
-
When is GT Biopharma's next earnings date?
Unfortunately, GT Biopharma's (GTBP) next earnings date is currently unknown.
-
Does GT Biopharma pay dividends?
No, GT Biopharma does not pay dividends.
-
How much money does GT Biopharma make?
GT Biopharma has a market capitalization of 8.04M. GT Biopharma made a loss 7.6M US dollars in net income (profit) last year or -$0.17 on an earnings per share basis.
-
What is GT Biopharma's stock symbol?
GT Biopharma, Inc. is traded on the NASDAQ under the ticker symbol "GTBP".
-
What is GT Biopharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of GT Biopharma?
Shares of GT Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are GT Biopharma's key executives?
GT Biopharma's management team includes the following people:
- Dr. Gregory I. Berk M.D. Pres of Research & Devlp, Chief Medical Off., Interim Chief Executive Officer and Mem. of Scientific Advisor Board(age: 67, pay: $2,500)
-
How many employees does GT Biopharma have?
As Jul 2024, GT Biopharma employs 2 workers.
-
When GT Biopharma went public?
GT Biopharma, Inc. is publicly traded company for more then 7 years since IPO on 27 Mar 2018.
-
What is GT Biopharma's official website?
The official website for GT Biopharma is gtbiopharma.com.
-
Where are GT Biopharma's headquarters?
GT Biopharma is headquartered at 8000 Marina Boulevard, Brisbane, CA.
-
How can i contact GT Biopharma?
GT Biopharma's mailing address is 8000 Marina Boulevard, Brisbane, CA and company can be reached via phone at +41 59194040.
GT Biopharma company profile:
GT Biopharma, Inc.
gtbiopharma.comNASDAQ
2
Biotechnology
Healthcare
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Brisbane, CA 94005
CIK: 0000109657
ISIN: US36254L3087
CUSIP: 36254L209
